REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD. |  |
|
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Mills Kenneth T. | Director | May 12 '25 | Option Exercise | 3.76 | 20,602 | 77,464 | 495,705 | May 14 04:49 PM | | Mills Kenneth T. | Director | May 12 '25 | Sale | 7.91 | 20,602 | 163,046 | 475,103 | May 14 04:49 PM | | KENNETH MILLS | Director | May 12 '25 | Proposed Sale | 7.52 | 20,602 | 154,927 | | May 12 04:29 PM | | Mills Kenneth T. | Director | Mar 27 '25 | Option Exercise | 3.76 | 30,752 | 115,628 | 475,103 | Mar 31 05:05 PM | | VITTAL VASISTA | Officer | Dec 30 '24 | Proposed Sale | 7.41 | 20,041 | 148,504 | | Dec 30 04:09 PM | | KARABELAS ARGERIS N | Director | Oct 01 '24 | Option Exercise | 3.76 | 10,000 | 37,600 | 21,286 | Oct 02 04:31 PM | | KARABELAS ARGERIS N | Director | Oct 01 '24 | Sale | 10.11 | 10,000 | 101,052 | 11,286 | Oct 02 04:31 PM | | KARABELAS ARGERIS N | Director | Sep 03 '24 | Option Exercise | 3.76 | 10,000 | 37,600 | 21,286 | Sep 04 08:20 PM | | KARABELAS ARGERIS N | Director | Sep 03 '24 | Sale | 11.56 | 10,000 | 115,588 | 11,286 | Sep 04 08:20 PM | | Mills Kenneth T. | Director | Aug 08 '24 | Option Exercise | 0.85 | 36,316 | 30,869 | 444,351 | Aug 12 04:58 PM | | KARABELAS ARGERIS N | Director | Aug 01 '24 | Option Exercise | 3.85 | 10,100 | 38,874 | 21,386 | Aug 05 06:39 PM | | KARABELAS ARGERIS N | Director | Aug 01 '24 | Sale | 13.51 | 10,100 | 136,454 | 11,286 | Aug 05 06:39 PM | | Simpson Curran | Chief Executive Officer | Aug 01 '24 | Sale | 15.00 | 100 | 1,500 | 170,037 | Aug 05 06:39 PM | | ARGERIS N KARABELAS | Director | Aug 01 '24 | Proposed Sale | 14.25 | 31,000 | 441,750 | | Aug 01 04:34 PM | | KARABELAS ARGERIS N | Director | Jul 29 '24 | Option Exercise | 12.74 | 11,000 | 140,140 | 22,286 | Jul 30 05:01 PM | | KARABELAS ARGERIS N | Director | Jul 29 '24 | Sale | 15.04 | 11,000 | 165,495 | 11,286 | Jul 30 05:01 PM | | Simpson Curran | Chief Executive Officer | Jul 29 '24 | Sale | 15.04 | 9,648 | 145,106 | 170,137 | Jul 30 05:01 PM | | CURRAN M SIMPSON | Director | Jul 29 '24 | Proposed Sale | 14.33 | 25,106 | 359,769 | | Jul 29 04:13 PM | | Mills Kenneth T. | Director | Jul 25 '24 | Option Exercise | 3.76 | 15,369 | 57,787 | 423,404 | Jul 26 05:00 PM | | Mills Kenneth T. | Director | Jul 24 '24 | Option Exercise | 3.76 | 12,221 | 45,951 | 420,256 | Jul 26 05:00 PM | | Mills Kenneth T. | Director | Jul 25 '24 | Sale | 13.96 | 15,369 | 214,501 | 408,035 | Jul 26 05:00 PM | | Mills Kenneth T. | Director | Jul 24 '24 | Sale | 13.78 | 12,221 | 168,433 | 408,035 | Jul 26 05:00 PM | | Mills Kenneth T. | Director | Jul 17 '24 | Option Exercise | 3.76 | 2,210 | 8,310 | 410,245 | Jul 18 05:05 PM | | Mills Kenneth T. | Director | Jul 16 '24 | Option Exercise | 3.76 | 200 | 752 | 408,235 | Jul 18 05:05 PM | | Mills Kenneth T. | Director | Jul 17 '24 | Sale | 13.77 | 2,210 | 30,440 | 408,035 | Jul 18 05:05 PM | | Mills Kenneth T. | Director | Jul 16 '24 | Sale | 13.76 | 200 | 2,752 | 408,035 | Jul 18 05:05 PM | | KARABELAS ARGERIS N | Director | Jul 01 '24 | Option Exercise | 3.76 | 10,000 | 37,600 | 21,286 | Jul 03 07:55 AM | | KARABELAS ARGERIS N | Director | Jul 01 '24 | Sale | 11.27 | 10,000 | 112,691 | 11,286 | Jul 03 07:55 AM |
|
